Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Elicio Therapeutics, Inc.ELTX · Entity 299 | Director · CEO, President and Director | July 16, 2026 | July 17, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Elicio Therapeutics, Inc.
Report date July 16, 2026 · Filed July 17, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.20 · Expires 2036-07-16 | Direct | 186,944 |
Reported balance
After 2026-07-16 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-07-16 · Grant · Acquired 186,944 · Balance 186,944 F1: The stock option vests and becomes exercisable as to 50% of the options on July 16, 2027, the first anniversary of the grant date, and as to the remaining 50% of the options on July 16, 2028, the second anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock option vests and becomes exercisable as to 50% of the options on July 16, 2027, the first anniversary of the grant date, and as to the remaining 50% of the options on July 16, 2028, the second anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 16, 2026 Filed Jul 17, 2026 20:13 UTC | Elicio Therapeutics, Inc. ELTX · Entity 299 | GrantStock Option (Right to Buy) · Derivative | 186,944 | $0.00 Strike: $3.20 | $0.00 |
DisclosureSEC source: 0001796436-26-000002 · wk-form4_1784319208.xml · derivative · entry 1 Connelly Robert · CIK 0001796436 · Director · CEO, President and Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 186,944 Underlying: Common Stock · 186,944 shares Expires 2036-07-16 F1 · derivative.exercise_date: The stock option vests and becomes exercisable as to 50% of the options on July 16, 2027, the first anniversary of the grant date, and as to the remaining 50% of the options on July 16, 2028, the second anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates. Read SEC document |
| February 02, 2026 Filed Feb 3, 2026 21:42 UTC | Elicio Therapeutics, Inc. ELTX · Entity 299 | GrantStock Option (Right to Buy) · Derivative | 147,200 | $0.00 Strike: $8.10 | $0.00 |
DisclosureSEC source: 0001601485-26-000010 · wk-form4_1770154928.xml · derivative · entry 2 Connelly Robert · CIK 0001796436 · Director · CEO, President and Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 147,200 Underlying: Common Stock · 147,200 shares Expires 2036-02-02 F2 · derivative.exercise_date: The stock option vests and becomes exercisable as to 25% of the options on February 2, 2027, the first anniversary of the grant date, with the remaining options vesting in monthly installments over a three-year period thereafter, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates. Read SEC document |
| February 02, 2026 Filed Feb 3, 2026 21:42 UTC | Elicio Therapeutics, Inc. ELTX · Entity 299 | GrantCommon Stock | 73,600 | $0.00 | $0.00 |
DisclosureSEC source: 0001601485-26-000010 · wk-form4_1770154928.xml · nonDerivative · entry 1 Connelly Robert · CIK 0001796436 · Director · CEO, President and Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 120,570 F1 · shares: Represents restricted stock units ("RSUs") that will vest as to 25% of the RSUs on February 2, 2027, the first anniversary of the grant date, with the remaining RSUs vesting in annual installments over a three-year period thereafter, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates. Each RSU represents the right to receive one share of common stock, par value $0.01 per share, of the Issuer. F1 · price: Represents restricted stock units ("RSUs") that will vest as to 25% of the RSUs on February 2, 2027, the first anniversary of the grant date, with the remaining RSUs vesting in annual installments over a three-year period thereafter, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates. Each RSU represents the right to receive one share of common stock, par value $0.01 per share, of the Issuer. Read SEC document |
| February 03, 2025 Filed Feb 4, 2025 21:08 UTC | Elicio Therapeutics, Inc. ELTX · Entity 299 | GrantStock Option (Right to Buy) · Derivative | 121,600 | $0.00 Strike: $8.92 | $0.00 |
DisclosureSEC source: 0001601485-25-000012 · wk-form4_1738703302.xml · derivative · entry 1 Connelly Robert · CIK 0001796436 · Director · CEO, President and Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 121,600 Underlying: Common Stock · 121,600 shares Expires 2035-02-03 F1 · derivative.exercise_date: The stock option vests and becomes exercisable as to 25% of the options on the first anniversary of the grant date (February 3, 2026), with the remaining options vesting in equal monthly installments over a three-year period thereafter, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates. Read SEC document |
| September 30, 2024 Filed Oct 2, 2024 20:14 UTC | Elicio Therapeutics, Inc. ELTX · Entity 299 | GrantStock Option (Right to Buy) · Derivative | 91,600 | $0.00 Strike: $5.03 | $0.00 |
DisclosureSEC source: 0001601485-24-000053 · wk-form4_1727900067.xml · derivative · entry 1 Connelly Robert · CIK 0001796436 · Director · CEO, President and Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 91,600 Underlying: Common Stock · 91,600 shares Expires 2034-09-30 F1 · derivative.exercise_date: Fifty percent (50%) of the stock options vest on September 30, 2025, the one-year anniversary of the grant date, with the remaining fifty percent (50%) of the stock options to vest on September 30, 2026, the two-year anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates. Read SEC document |
| February 01, 2024 Filed Feb 5, 2024 11:01 UTC | Elicio Therapeutics, Inc. ELTX · Entity 299 | GrantStock Option (right to buy) · Derivative | 225,137 | $0.00 Strike: $4.50 | $0.00 |
DisclosureSEC source: 0001140361-24-005498 · form4.xml · derivative · entry 1 Connelly Robert · CIK 0001796436 · Director · CEO, President and Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 225,137 Underlying: Common Stock · 225,137 shares Expires 2034-02-01 F1 · derivative.exercise_date: Twenty five percent (25%) of the stock options vest on February 1, 2025, the one-year anniversary of the grant date, with the remaining options vesting in monthly installments over a three-year period thereafter, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.